| Endpoints | Group A: DM2 on Metformin pre-HTx (n=21) | Group B: DM2 on Metformin post-HTx (n=22) | Group C: DM2 on Metformin pre-HTx and post-HTx (n=10) | Group D: Control Group w/o Metformin Use (n=176) | P-Value |
|---|---|---|---|---|---|
| 1 Year Survival | 76.2% | 95.5% | 100.0% | 92.0% | 0.076* |
| 1 Year Freedom from CAV | 95.2% | 90.9% | 90.0% | 95.5% | 0.779 |
| 1 Year Freedom from NF-MACE | 85.7% | 72.7% | 90.0% | 83.0% | 0.647 |
| 1 Year Freedom from Any-Treated Rejection | 76.2% | 86.4% | 90.0% | 88.6% | 0.442 |
| 1 Year Freedom from Acute Cellular Rejection | 90.5% | 100.0% | 100.0% | 96.0% | 0.391 |
| 1 Year Freedom from Antibody-Mediated Rejection | 90.5% | 100.0% | 90.0% | 93.2% | 0.562 |
*Pairwise analysis between Group A and Group D, p=0.038